Table 2.

Factors associated with mortality, unadjusted and adjusted analyses

		Unadjusted analysis (N=3270)		Adjusted analysis* (N=3094)
	Rate/100py	Hazard Ratio (HR)	95% CI (P value)	Hazard Ratio (HR)	95% CI (P value)
IPT
No	11.10	1	P<0.001	1	P=0.002
Yes	3.71	0.34	0.24 – 0.49	0.51	0.32 – 0.80
Gender
Male	9.29	1	P=0.005
Female	3.82	0.42	0.21 – 0.84
Age (years)
18–29	4.86	1	PT <0.001	1.00	PT <0.001
30 – 39	6.74	1.38	0.77 – 2.47	0.99	0.55 – 1.78
40–49	11.53	2.24	1.29 – 3.89	1.58	0.90 – 2.77
≥ 50	10.20	2.06	1.15 – 3.71	1.80	0.99 – 3.27
Baseline WHO stage
1 or 2	6.36	1	PT<0.001	1	PT=0.005
3	9.66	1.49	1.13 – 1.98	1.06	0.86 – 1.57
4	21.68	3.27	2.38 – 4.50	1.75	1.21 – 2.54
Baseline CD4 (cells/μl)
<50	19.34	4.11	2.79 – 6.06	3.58	2.39 – 5.36
50–100	12.91	2.78	1.87 – 4.14	2.57	1.72 – 3.83
101 – 150	9.08	1.97	1.30 – 2.99	1.93	1.27 – 2.94
151 – 200	3.81	0.84	0.50 – 1.42	0.86	0.51 – 1.46
>200	4.58	1	PT <0.001	1	PT<0.001
Baseline viral load (copies/ml)
≤ 100,000	6.85	1	P<0.001
>100,000	11.77	1.70	1.29 – 2.24
Year started ART
2004	15.10	1	PT<0.001	1	PT=0.001
2005	9.98	0.67	0.49 – 0.92	0.78	0.55 – 1.11
2006	6.75	0.46	0.33 – 0.64	0.58	0.1 – 0.83
2007	5.62	0.38	0.26 – 0.55	0.60	0.41 – 0.89
Cotrimoxazole started**
No	9.85	1	P=0.001
Yes	7.57	0.78	0.60 – 1.00
Previous TB
No	8.88	1	P=0.97
Yes	9.19	1.01	0.62 – 1.63
Baseline Haemoglobin (g/dl)
<10	26.28	1	P<0.001
≥ 10	5.51	4.58	3.37 – 6.24
Viral response at 6 wks (>1 log decrease)
No	8.32	1	P<0.001
Yes	3.01	0.36	0.22 – 0.59
Company (clinic site)
Company A	9.70	1	P=0.002	1	P=0.29
Company B	4.40	0.45	0.27 – 0.73	0.74	0.43 – 1.31
Company C	8.83	0.95	0.57 – 1.57	1.37	0.80 – 2.35

P^T = P value for linear trend

^*Adjusted for age group, baseline WHO stage, baseline CD4 count, year started on ART, and company.

^**Cotrimoxazole refers to those put on either cotrimoxazole or dapsone (used in cases of cotrimoxazole hypersensitivity)

IPT: isoniazid preventive therapy; ART: antiretroviral therapy